Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Characteristics of Kenyan Women Enrolled in a Trial on Doxycycline Postexposure Prophylaxis for Sexually Transmitted Infection Prevention

View ORCID ProfileKevin Oware, Lydia Adiema, Bernard Rono, Lauren R. Violette, R. Scott McClelland, Deborah Donnell, Caitlin W. Scoville, Josephine Odoyo, Jared M. Baeten, View ORCID ProfileElizabeth Bukusi, Jenell Stewart
doi: https://doi.org/10.1101/2022.04.01.22273292
Kevin Oware
1Kenya Medical Research Institute (KEMRI), Kisumu, Kenya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kevin Oware
  • For correspondence: kkamolloh@kemri-ucsf.org kamolloh2005@gmail.com
Lydia Adiema
1Kenya Medical Research Institute (KEMRI), Kisumu, Kenya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernard Rono
1Kenya Medical Research Institute (KEMRI), Kisumu, Kenya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauren R. Violette
3Medicine (Infectious Diseases), University of Washington, Seattle, United States
4Epidemiology, University of Washington, Seattle, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Scott McClelland
2Departments of Global Health, University of Washington, Seattle, United States
3Medicine (Infectious Diseases), University of Washington, Seattle, United States
4Epidemiology, University of Washington, Seattle, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deborah Donnell
6Fred Hutchinson Cancer Research Center, Seattle, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caitlin W. Scoville
2Departments of Global Health, University of Washington, Seattle, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Josephine Odoyo
1Kenya Medical Research Institute (KEMRI), Kisumu, Kenya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jared M. Baeten
2Departments of Global Health, University of Washington, Seattle, United States
3Medicine (Infectious Diseases), University of Washington, Seattle, United States
4Epidemiology, University of Washington, Seattle, United States
7Gilead Sciences, Foster City, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth Bukusi
1Kenya Medical Research Institute (KEMRI), Kisumu, Kenya
2Departments of Global Health, University of Washington, Seattle, United States
5Obstetrics and Gynaecology, University of Washington, Seattle, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Elizabeth Bukusi
Jenell Stewart
2Departments of Global Health, University of Washington, Seattle, United States
3Medicine (Infectious Diseases), University of Washington, Seattle, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Introduction The global incidence of sexually transmitted infections (STIs) has been rapidly increasing over the past decade, with more than one million curable STIs being acquired daily. Young women in sub-Saharan Africa have a high prevalence and incidence of both curable STIs and HIV. The use of doxycycline as a prophylaxis to prevent STI infections is promising; however, clinical trials, to date, have only been conducted among men who have sex with men (MSM) in high-income settings. We describe the characteristics of participants enrolled in the first trial to determine the efficacy of doxycycline post-exposure prophylaxis (PEP) to reduce STI incidence among women.

Methods This is an open-label 1:1 randomized clinical trial of doxycycline PEP efficacy to reduce incident bacterial STIs – Neisseria gonorrhoeae, Chlamydia trachomatis, and Treponema pallidum – among Kenyan women aged ≥18 and ≤30 years. All were also taking HIV pre-exposure prophylaxis (PrEP). We describe the baseline characteristics of participants.

Results Between February 2020 and November 2021, 449 women were enrolled. The median age was 24 years (IQR 21-27), the majority were never married (66.1%), 370 women (82.4%) reported having a primary sex partner, and 33% had sex with new partners in the 3 months prior to enrolment. Two-thirds (67.5%, 268 women) did not use condoms, 36.7% reported transactional sex, and 43.2% suspected their male partners of having sex with other women. Slightly less than half (45.9%, 206 women) were recently concerned about being exposed to an STI. The prevalence of STIs was 17.9%, with C. trachomatis accounting for the majority of infections.

Conclusion Young cisgender women using HIV PrEP in Kenya and enrolled in a trial of doxycycline postexposure prophylaxis had a high prevalence of curable STIs and represent a target population for an STI prevention intervention.

Competing Interest Statement

Dr. McClelland has received honoraria for consulting for Lupin Pharmaceuticals and research funding, paid to the University of Washington, from Hologic Corporation. Dr. Baeten is an employee of Gilead Sciences outside of the submitted work. The author and all other co-authors declared that no competing interests exist.

Clinical Trial

NCT04050540

Funding Statement

Jared M. Baeten received funding from US National Institutes of Health (grants R01AI145971, P30AI027757, K23MH124466). The funder played no role in the design, data collection and analysis, decision to publish, or preparation of this manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Kenya Medical Research Institute's Scientific and Ethical Review Unit and University of Washington's Institutional Review Board

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Conflict of interest: Dr. McClelland has received honoraria for consulting for Lupin Pharmaceuticals and research funding, paid to the University of Washington, from Hologic Corporation. Dr. Baeten is an employee of Gilead Sciences outside of the submitted work. The author and all other co-authors do not have any declared conflict of interest.

Data Availability

All relevant data are within the manuscript.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
Back to top
PreviousNext
Posted April 01, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Characteristics of Kenyan Women Enrolled in a Trial on Doxycycline Postexposure Prophylaxis for Sexually Transmitted Infection Prevention
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Characteristics of Kenyan Women Enrolled in a Trial on Doxycycline Postexposure Prophylaxis for Sexually Transmitted Infection Prevention
Kevin Oware, Lydia Adiema, Bernard Rono, Lauren R. Violette, R. Scott McClelland, Deborah Donnell, Caitlin W. Scoville, Josephine Odoyo, Jared M. Baeten, Elizabeth Bukusi, Jenell Stewart
medRxiv 2022.04.01.22273292; doi: https://doi.org/10.1101/2022.04.01.22273292
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Characteristics of Kenyan Women Enrolled in a Trial on Doxycycline Postexposure Prophylaxis for Sexually Transmitted Infection Prevention
Kevin Oware, Lydia Adiema, Bernard Rono, Lauren R. Violette, R. Scott McClelland, Deborah Donnell, Caitlin W. Scoville, Josephine Odoyo, Jared M. Baeten, Elizabeth Bukusi, Jenell Stewart
medRxiv 2022.04.01.22273292; doi: https://doi.org/10.1101/2022.04.01.22273292

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Sexual and Reproductive Health
Subject Areas
All Articles
  • Addiction Medicine (230)
  • Allergy and Immunology (507)
  • Anesthesia (111)
  • Cardiovascular Medicine (1264)
  • Dentistry and Oral Medicine (207)
  • Dermatology (148)
  • Emergency Medicine (283)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (538)
  • Epidemiology (10056)
  • Forensic Medicine (5)
  • Gastroenterology (502)
  • Genetic and Genomic Medicine (2486)
  • Geriatric Medicine (240)
  • Health Economics (482)
  • Health Informatics (1653)
  • Health Policy (757)
  • Health Systems and Quality Improvement (638)
  • Hematology (250)
  • HIV/AIDS (538)
  • Infectious Diseases (except HIV/AIDS) (11896)
  • Intensive Care and Critical Care Medicine (627)
  • Medical Education (255)
  • Medical Ethics (75)
  • Nephrology (269)
  • Neurology (2304)
  • Nursing (140)
  • Nutrition (354)
  • Obstetrics and Gynecology (458)
  • Occupational and Environmental Health (537)
  • Oncology (1259)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (326)
  • Pediatrics (737)
  • Pharmacology and Therapeutics (315)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2295)
  • Public and Global Health (4850)
  • Radiology and Imaging (846)
  • Rehabilitation Medicine and Physical Therapy (493)
  • Respiratory Medicine (657)
  • Rheumatology (289)
  • Sexual and Reproductive Health (241)
  • Sports Medicine (228)
  • Surgery (273)
  • Toxicology (44)
  • Transplantation (131)
  • Urology (100)